SCHEMBL25849354

SCHEMBL25849354

CNS(=O)(=O)c1ccc(C(=O)NCc2ccc(NC(C)C)cc2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
PKM P14618 1/20 0.40
HDAC3 O15379 3/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC4 P56524 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.38
EPHX2 P34913 2/20 0.38
NR1H4 Q96RI1 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.38
NAMPT P43490 1/20 0.37
AKT3 Q9Y243 1/20 0.37
PPARA Q07869 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 1/20 0.36
ESRRG P62508 1/20 0.36
ADAMTS4 O75173 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24196383 0.88 EPHX2 (0.42) KMT2AMEN1PKMHDAC3HDAC1
SCHEMBL25848782 0.86 KMT2A (0.49) KMT2AMEN1HDAC3HDAC1HDAC4
SCHEMBL25848775 0.84 MEN1 (0.52) KMT2AMEN1PKMTDP1SMN1; SMN2
SCHEMBL25848884 0.83 CCR1 (0.47) KMT2AMEN1HDAC3HDAC1HDAC4
SCHEMBL25848928 0.83 CA1 (0.46) KMT2AMEN1HDAC3HDAC1HDAC4
SCHEMBL25848797 0.83 NR1H4 (0.50) HDAC3HDAC1HDAC4HDAC6TP53
SCHEMBL25848828 0.81 EPHX2 (0.53) KMT2AMEN1HDAC3HDAC6EPHX2
SCHEMBL25849324 0.80 PPARA (0.49) HDAC3HDAC1HDAC4HDAC6EPHX2
SCHEMBL25304098 0.80 EPHX2 (0.48) KMT2AMEN1HDAC3HDAC1HDAC4
SCHEMBL25304254 0.80 HDAC3 (0.45) KMT2AMEN1HDAC3HDAC1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 KMT2A 232/4885MEN1 1117/4885PKM 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.